Eyenovia Net Worth
Eyenovia Net Worth Breakdown | EYEN |
Eyenovia Net Worth Analysis
Eyenovia's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eyenovia's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eyenovia's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eyenovia's net worth analysis. One common approach is to calculate Eyenovia's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eyenovia's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eyenovia's net worth. This approach calculates the present value of Eyenovia's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eyenovia's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eyenovia's net worth. This involves comparing Eyenovia's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eyenovia's net worth relative to its peers.
Enterprise Value |
|
To determine if Eyenovia is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eyenovia's net worth research are outlined below:
| Eyenovia generated a negative expected return over the last 90 days | |
| Eyenovia has high historical volatility and very poor performance | |
| Eyenovia has some characteristics of a very speculative penny stock | |
| Eyenovia has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.79 K. Net Loss for the year was (27.26 M) with profit before overhead, payroll, taxes, and interest of 12.4 M. | |
| Eyenovia currently holds about 21.51 M in cash with (23.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eyenovia has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Eyenovia Provides Update on Restructuring Efforts |
Eyenovia uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eyenovia. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eyenovia's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Eyenovia's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eyenovia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyenovia backward and forwards among themselves. Eyenovia's institutional investor refers to the entity that pools money to purchase Eyenovia's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 93.4 K | Nations Financial Group Inc | 2024-09-30 | 90.9 K | Hrt Financial Llc | 2024-06-30 | 88.6 K | Susquehanna International Group, Llp | 2024-06-30 | 87.3 K | Financial Management Network, Inc | 2024-09-30 | 81.2 K | Pfg Investments, Llc | 2024-09-30 | 70 K | Lpl Financial Corp | 2024-09-30 | 64.5 K | Bank Of America Corp | 2024-06-30 | 61.6 K | Northern Trust Corp | 2024-09-30 | 61.5 K | Armistice Capital, Llc | 2024-09-30 | 8.5 M | Vanguard Group Inc | 2024-09-30 | 1.9 M |
Follow Eyenovia's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.3 M.Market Cap |
|
Project Eyenovia's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (0.95) | (0.99) | |
| Return On Equity | (3.03) | (3.18) |
When accessing Eyenovia's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eyenovia's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eyenovia's profitability and make more informed investment decisions.
Evaluate Eyenovia's management efficiency
Eyenovia has return on total asset (ROA) of (0.9294) % which means that it has lost $0.9294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.1466) %, meaning that it created substantial loss on money invested by shareholders. Eyenovia's management efficiency ratios could be used to measure how well Eyenovia manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -1.07. In addition to that, Return On Capital Employed is likely to drop to -1.39. At this time, Eyenovia's Debt To Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.22 | 0.21 | |
| Tangible Book Value Per Share | 0.17 | 0.16 | |
| Enterprise Value Over EBITDA | (3.59) | (3.77) | |
| Price Book Value Ratio | 9.48 | 15.46 | |
| Enterprise Value Multiple | (3.59) | (3.77) | |
| Price Fair Value | 9.48 | 15.46 | |
| Enterprise Value | 86.6 M | 78.4 M |
Eyenovia benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Enterprise Value Revenue 475.1396 | Revenue 31.4 K | Quarterly Revenue Growth 4 | Revenue Per Share 0.001 | Return On Equity (9.15) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyenovia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyenovia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eyenovia insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eyenovia time-series forecasting models is one of many Eyenovia's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eyenovia's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Eyenovia Earnings per Share Projection vs Actual
Eyenovia Corporate Management
| Andrew Jones | Chief Officer | Profile | |
| Bren Kern | VP Operations | Profile | |
| Tony Cardinale | Vice Sales | Profile | |
| Norbert Lowe | Senior Operations | Profile | |
| Alexander Lobo | Investor Contact | Profile | |
| MD MPH | President, CoFounder | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.001 | Quarterly Revenue Growth 4 | Return On Assets (0.93) | Return On Equity (9.15) |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.